Toviaz
Product Images NDC 69189-0242

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 69189-0242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine Er 4 mg Tablet Label (6918902421)

Fesoterodine fumarate ER is a medication represented by Toviaz 4mg tablet manufactured by Pfizer. The hospital lot number is APF15J05-M and the expiration date is 10/04/2016. NDC number for the product is 6918902421. This medication was available at Avera McKennan hospital located in Sioux Falls.*

FDA Label Image

Chemical Structure (Toviaz 01)

FDA Label Image

Figure 1 (Toviaz 02)

The text shows the mean change from baseline in the number of micturitions per 24 hours. It includes a figure depicting the change in the number of micturitions per 24 hours over weeks 2, 8, and 12. The study involved a placebo group (N=279) and a Toviaz treatment group (65). There is no further information available.*

FDA Label Image

Figure 2 (Toviaz 03)

The image shows the change in urge incontinence episodes per 24 hours over 12 weeks in Study 1, with data for the placebo group (N=211) and two doses of Toviaz (N=199 for 4mg and N=223 for 8mg). The y-axis displays the change from baseline in urge incontinence episodes per 24 hours and the x-axis displays the weeks.*

FDA Label Image

Figure 3 (Toviaz 04)

This is a report on a clinical study. The mean change from the baseline in the frequency of urination (number of micturitions per 24 hours) was -0.5. Figure 3 shows the change in the number of micturitions per 24 hours over a period of 12 weeks in Study 2, with data points at 2, 8, and 12 weeks. The study had three groups: a Placebo group with 266 participants, a Toviazdmg group with 267 participants, and a Tovazsmg group with 267 participants.*

FDA Label Image

Figure 4 (Toviaz 05)

This is a graph showing the change in urge incontinence episodes per 24 hours in Study 2 over the course of 12 weeks for three different groups: a placebo group (205 participants), a Toviaz 4mg group (228 participants), and a Toviaz 8mg group (218 participants). The y-axis measures the change in episodes while the x-axis measures the weeks of the study.*

FDA Label Image

Logo (Toviaz 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.